By Justin Petrone

CombiMatrix Molecular Diagnostics will soon launch an array-based cancer diagnostic that contains "thorough coverage of all the key oncogenes and cancer-related chromosomal regions."

Called the DNAarray Oligo 180K Heme Profile, the new test contains content endorsed by the Cancer Cytogenomics Microarray Consortium, according to CombiMatrix CEO Judd Jessup.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.